Baird Financial Group Inc. Acquires 4,878 Shares of Health Catalyst, Inc. (NASDAQ:HCAT)

Baird Financial Group Inc. increased its holdings in shares of Health Catalyst, Inc. (NASDAQ:HCATGet Rating) by 44.0% during the 2nd quarter, HoldingsChannel reports. The firm owned 15,971 shares of the company’s stock after purchasing an additional 4,878 shares during the period. Baird Financial Group Inc.’s holdings in Health Catalyst were worth $231,000 as of its most recent SEC filing.

Other institutional investors have also modified their holdings of the company. Fairfield Bush & CO. bought a new position in shares of Health Catalyst during the 1st quarter valued at about $25,000. Manchester Capital Management LLC lifted its holdings in shares of Health Catalyst by 667.5% during the 1st quarter. Manchester Capital Management LLC now owns 1,159 shares of the company’s stock valued at $30,000 after purchasing an additional 1,008 shares in the last quarter. Point72 Hong Kong Ltd bought a new position in shares of Health Catalyst during the 1st quarter valued at about $33,000. Advisor Group Holdings Inc. lifted its stake in Health Catalyst by 86.3% in the 1st quarter. Advisor Group Holdings Inc. now owns 5,324 shares of the company’s stock valued at $137,000 after acquiring an additional 2,467 shares in the last quarter. Finally, Arizona State Retirement System lifted its stake in Health Catalyst by 6.1% in the 2nd quarter. Arizona State Retirement System now owns 12,696 shares of the company’s stock valued at $184,000 after acquiring an additional 735 shares in the last quarter. Institutional investors own 96.58% of the company’s stock.

Health Catalyst Stock Up 6.5 %

HCAT stock opened at $9.98 on Thursday. The company has a current ratio of 4.87, a quick ratio of 4.87 and a debt-to-equity ratio of 0.51. The firm has a market capitalization of $546.41 million, a PE ratio of -3.35 and a beta of 1.18. Health Catalyst, Inc. has a 1-year low of $6.40 and a 1-year high of $45.56. The business’s 50 day simple moving average is $9.36 and its 200 day simple moving average is $12.43.

Health Catalyst (NASDAQ:HCATGet Rating) last posted its earnings results on Tuesday, November 8th. The company reported ($0.45) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.53) by $0.08. The business had revenue of $68.35 million for the quarter, compared to analyst estimates of $66.85 million. Health Catalyst had a negative return on equity of 19.05% and a negative net margin of 55.42%. As a group, research analysts anticipate that Health Catalyst, Inc. will post -1.66 EPS for the current year.

Insider Buying and Selling

In other Health Catalyst news, CEO Daniel D. Burton bought 197,078 shares of the firm’s stock in a transaction that occurred on Friday, November 11th. The shares were acquired at an average cost of $10.14 per share, with a total value of $1,998,370.92. Following the acquisition, the chief executive officer now owns 900,140 shares of the company’s stock, valued at $9,127,419.60. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 1.50% of the stock is owned by insiders.

Analyst Ratings Changes

HCAT has been the topic of several research reports. Piper Sandler cut their target price on Health Catalyst from $11.00 to $8.00 in a research note on Wednesday, November 9th. Stifel Nicolaus cut Health Catalyst from a “buy” rating to a “hold” rating and cut their target price for the company from $27.00 to $16.00 in a research note on Friday, August 5th. Wells Fargo & Company initiated coverage on Health Catalyst in a research note on Monday, October 31st. They issued an “equal weight” rating and a $10.00 target price on the stock. Canaccord Genuity Group cut their target price on Health Catalyst from $19.00 to $15.00 and set a “buy” rating on the stock in a research note on Wednesday, November 9th. Finally, SVB Leerink lowered their price target on Health Catalyst from $20.00 to $17.00 and set an “outperform” rating on the stock in a research report on Wednesday, November 9th. Six analysts have rated the stock with a hold rating, eight have assigned a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, Health Catalyst currently has a consensus rating of “Moderate Buy” and an average price target of $18.53.

Health Catalyst Profile

(Get Rating)

Health Catalyst, Inc engages in the provision of data and analytics technology and services to healthcare organizations. It operates through the Technology, and Professional Services segments. The Technology segment includes its data platform, analytics applications, and support services. The Professional Services segment combines analytics, implementation, strategic advisory, outsource, and improvement services to deliver expertise to its customers.

Read More

Want to see what other hedge funds are holding HCAT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Health Catalyst, Inc. (NASDAQ:HCATGet Rating).

Institutional Ownership by Quarter for Health Catalyst (NASDAQ:HCAT)

Receive News & Ratings for Health Catalyst Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Health Catalyst and related companies with MarketBeat.com's FREE daily email newsletter.